# PDUFA dates December 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-12

> 74 FDA catalysts are dated in December 2026, including 8 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in December 2026?

PDUFA dates in December 2026: zanzalintinib (EXEL) on December 3, 2026; imsidolimab (VNDA) on December 12, 2026; Lifyorli™ (relacorilant, CORT) on December 17, 2026; lorundrostat (MLYS) on December 22, 2026; anitocabtagene autoleucel (GILD) on December 23, 2026; MR-107A (VTRS) on December 27, 2026; and 2 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-12)

Source: Press release filed with the SEC (EX-99), accession 0000939767-26-000058, https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm (retrieved 2026-11-12). Last confirmed 2026-10-29. Cite: https://sec-api.dev/fda-calendar/2026-12#answer

## PDUFA dates in December 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| December 3, 2026 | EXELIXIS, INC. | EXEL | zanzalintinib | previously treated metastatic colorectal cancer | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm) |
| December 12, 2026 | Vanda Pharmaceuticals Inc. | VNDA | imsidolimab |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm) |
| December 17, 2026 | CORCEPT THERAPEUTICS INC | CORT | Lifyorli™ (relacorilant) | Cushing's syndrome - New Drug Application for relacorilant resubmitted | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm) |
| December 22, 2026 | Mineralys Therapeutics, Inc. | MLYS | lorundrostat | hypertension in combination with other antihypertensive drugs | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000142/mlys2026q38kex991.htm) |
| December 23, 2026 | GILEAD SCIENCES, INC. | GILD | anitocabtagene autoleucel | relapsed or refractory multiple myeloma | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm) |
| December 27, 2026 | Viatris Inc | VTRS | MR-107A | moderate-to-severe acute pain | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/exhibit991-2q26earningsrel.htm) |
| December 27, 2026 | Praxis Precision Medicines, Inc. | PRAX | relutrigine | SCN2A and SCN8A developmental and epileptic encephalopathies | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000091/praxis_investorxdayx2026.htm) |
| December 30, 2026 | Cogent Biosciences, Inc. | COGT | bezuclastinib | NonAdvanced Systemic Mastocytosis | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm) |

## All catalysts in December 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 2026 | [Erleada (apalutamide) primary completion](https://sec-api.dev/pdufa/apalutamide) | JNJ | Prostatic Neoplasms | scheduled | "NCT03767244 (A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03767244)) |
| December 2026 | [Descartes-08 primary completion](https://sec-api.dev/pdufa/descartes-08) | RNAC | Systemic Lupus Erythematosus (SLE) | scheduled | "NCT06038474 (Descartes-08 for Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Cartesian Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06038474)) |
| December 2026 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Antibody-mediated Rejection | scheduled | "NCT06685757 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685757)) |
| December 2026 | [PCV21 primary completion](https://sec-api.dev/pdufa/pcv21) | SNY | Pneumococcal Infections | scheduled | "NCT06838000 (Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06838000)) |
| December 2026 | [NEREUSTM (tradipitant) primary completion](https://sec-api.dev/pdufa/tradipitant) | VNDA | Nausea and Vomiting; Obesity | scheduled | "NCT07446439 (A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07446439)) |
| December 2026 | [Ritlecitinib higher dose primary completion](https://sec-api.dev/pdufa/ritlecitinib-higher-dose) | PFE | Severe Alopecia Areata | scheduled | "NCT07029711 (A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029711)) |
| December 3, 2026 | [Zanzalintinib PDUFA date](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | previously treated metastatic colorectal cancer | scheduled | ""Our first New Drug Application for zanzalintinib, for its initial potential indication in previously treated metastatic colorectal cancer, was accepted by U.S. regulatory authorities and is under active review, with a target action date of December 3, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm)) |
| December 2026 | [REGN7999 primary completion](https://sec-api.dev/pdufa/regn7999) | REGN | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | scheduled | "NCT06421636 (A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06421636)) |
| December 2026 | [Luxdegalutamide primary completion](https://sec-api.dev/pdufa/luxdegalutamide) | NVS | Metastatic Hormone-sensitive Prostate Cancer | scheduled | "NCT06991556 (An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991556)) |
| December 2026 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | scheduled | "NCT07500506 (A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07500506)) |
| December 2026 | [Soliris (eculizumab) primary completion](https://sec-api.dev/pdufa/eculizumab) | AZN | NMOSD; Neuromyelitis Optica Spectrum Disorders | scheduled | "NCT06724809 (Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-07 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06724809)) |
| December 2026 | [Milvexian primary completion](https://sec-api.dev/pdufa/milvexian) | JNJ | Atrial Fibrillation | scheduled | "NCT05757869 (A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05757869)) |
| December 2026 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Hidradenitis Suppurativa | scheduled | "NCT07228390 (A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07228390)) |
| December 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT06126224 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-09 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06126224)) |
| December 2026 | [Baxdrostat/dapagliflozin primary completion](https://sec-api.dev/pdufa/baxdrostat-dapagliflozin) | AZN | Chronic Kidney Disease and Hypertension | scheduled | "NCT07222917 (A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222917)) |
| December 2026 | [OJJAARA (momelotinib) primary completion](https://sec-api.dev/pdufa/momelotinib) | GSK | Primary Myelofibrosis | scheduled | "NCT03441113 (Extended Access of Momelotinib in Adults With Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03441113)) |
| December 2026 | [Disitamab vedotin primary completion](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT04879329 (A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04879329)) |
| December 12, 2026 | [Imsidolimab PDUFA date](https://sec-api.dev/pdufa/imsidolimab) | VNDA |  | scheduled | "•QuimilzaTM (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm)) |
| December 2026 | [BMS-986435 primary completion](https://sec-api.dev/pdufa/bms-986435) | BMY | Heart Failure | scheduled | "NCT06122779 (Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06122779)) |
| December 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Carcinoma | scheduled | "NCT06317311 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06317311)) |
| December 2026 | [ABP-234 primary completion](https://sec-api.dev/pdufa/abp-234) | AMGN | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06430866 (Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06430866)) |
| December 2026 | [PCV-20 primary completion](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06806137 (A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06806137)) |
| December 2026 | [NNC0662-0419 primary completion](https://sec-api.dev/pdufa/nnc0662-0419) | NVO | Overweight; Obesity | scheduled | "NCT07184632 (A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184632)) |
| December 2026 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | scheduled | "NCT05327114 (Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05327114)) |
| December 2026 | [XL092 primary completion](https://sec-api.dev/pdufa/xl092) | EXEL | Non-Clear Cell Renal Cell Carcinoma | scheduled | "NCT05678673 (Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05678673)) |
| December 2026 | [Gefurulimab primary completion](https://sec-api.dev/pdufa/gefurulimab) | AZN | Generalized Myasthenia Gravis; gMG | scheduled | "NCT06607627 (PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06607627)) |
| December 2026 | [CERUS CORP primary completion](https://sec-api.dev/companies/cers/catalysts) | CERS | Healthy Subjects | scheduled | "NCT07015437 (A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Cerus Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015437)) |
| December 17, 2026 | [Lifyorli™ (relacorilant) NDA/BLA submission](https://sec-api.dev/pdufa/relacorilant) | CORT | with Cushing's syndrome | scheduled | "resubmission of our NDA for relacorilant for the treatment of patients with Cushing's syndrome and our expectation that the FDA will issue a decision on this NDA by December 17, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm)) |
| December 17, 2026 | [Lifyorli™ (relacorilant) PDUFA date](https://sec-api.dev/pdufa/relacorilant) | CORT | Cushing's syndrome - New Drug Application for relacorilant resubmitted | scheduled | "•Relacorilant for patients with Cushing's syndrome - Resubmitted New Drug Application Prescription Drug User Fee Act (PDUFA) date of December 17, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000162828026069494/cort110326ex991pressrelease.htm)) |
| December 2026 | [BMS-986446 primary completion](https://sec-api.dev/pdufa/bms-986446) | BMY | Alzheimer Disease, Early Onset | scheduled | "NCT06268886 (Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06268886)) |
| December 2026 | [Brivekimig primary completion](https://sec-api.dev/pdufa/brivekimig) | SNY | Crohn's Disease | scheduled | "NCT06958536 (A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06958536)) |
| December 2026 | [Brivekimig primary completion](https://sec-api.dev/pdufa/brivekimig) | SNY | Ulcerative Colitis | scheduled | "NCT06975722 (A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975722)) |
| December 2026 | [TAK-861 primary completion](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy | scheduled | "NCT07363720 (A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363720)) |
| December 22, 2026 | [Lorundrostat PDUFA date](https://sec-api.dev/pdufa/lorundrostat) | MLYS | hypertension in combination with other antihypertensive drugs | scheduled | "- Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 -" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000142/mlys2026q38kex991.htm)) |
| December 2026 | [JNJ-64042056 primary completion](https://sec-api.dev/pdufa/jnj-64042056) | JNJ | Alzheimer Disease | scheduled | "NCT06544616 (A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-22 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544616)) |
| December 23, 2026 | [Anitocabtagene autoleucel PDUFA date](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | relapsed or refractory multiple myeloma | scheduled | "•Announced that the Biologics License Application for anito-cel in 4L+ R/R MM has been accepted by FDA, with a PDUFA target action date of December 23, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm)) |
| December 2026 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Asthma | scheduled | "NCT05692180 (A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05692180)) |
| December 2026 | [AAA617 primary completion](https://sec-api.dev/pdufa/aaa617) | NVS | Prostatic Neoplasm | scheduled | "NCT05849298 (A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05849298)) |
| December 2026 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion | scheduled | "NCT06500702 (A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06500702)) |
| December 2026 | [PCV-20 primary completion](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06740630 (A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06740630)) |
| December 2026 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Chronic Spontaneous Urticaria | scheduled | "NCT07219615 (A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219615)) |
| December 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT06212999 (A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-26 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06212999)) |
| December 27, 2026 | [MR-107A PDUFA date](https://sec-api.dev/pdufa/mr-107a) | VTRS | moderate-to-severe acute pain | scheduled | "in May, the Company announced that the FDA accepted for review the New Drug Application for MR-107A-02 (fast-acting meloxicam), a non-opioid, for the treatment of moderate-to-severe acute pain and the FDA has assigned a PDUFA goal date of December 27, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1792044/000179204426000037/exhibit991-2q26earningsrel.htm)) |
| December 27, 2026 | [Relutrigine PDUFA date](https://sec-api.dev/pdufa/relutrigine) | PRAX | SCN2A and SCN8A developmental and epileptic encephalopathies | scheduled | "56 D E V E L O P M E N T A L & E P I L E P T I C E N C E P H A L O P A T H I E S Relutrigine First medicine designed for SCN2A and SCN8A DEEs Dec 27, 2026 PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1689548/000168954826000091/praxis_investorxdayx2026.htm)) |
| December 2026 | [ZEJULA (niraparib) primary completion](https://sec-api.dev/pdufa/niraparib) | GSK | Ovarian Neoplasms; Breast Neoplasms | scheduled | "NCT04641247 (A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04641247)) |
| December 2026 | [HFA-152A primary completion](https://sec-api.dev/pdufa/hfa-152a) | GSK | Asthma | scheduled | "NCT07645248 (A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07645248)) |
| December 2026 | [Praluent (alirocumab) primary completion](https://sec-api.dev/pdufa/alirocumab) | REGN | Hypercholesterolemia | scheduled | "NCT07477704 (A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07477704)) |
| December 30, 2026 | [Bezuclastinib PDUFA date](https://sec-api.dev/pdufa/bezuclastinib) | COGT | NonAdvanced Systemic Mastocytosis | scheduled | "Potential FDA approval of bezuclastinib in NonAdvSM - PDUFA date of December 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| December 2026 | [Gemzar (gemcitabine) primary completion](https://sec-api.dev/pdufa/gemcitabine) | JNJ | Urinary Bladder Neoplasms | scheduled | "NCT04658862 (A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04658862)) |
| December 2026 | [NEO100 (NEO100) primary completion](https://sec-api.dev/pdufa/neo100) | NTHI | Residual, Progressive or Recurrent Grade II or III Meningioma | scheduled | "NCT05023018 (NEO100 and High-Grade Meningioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Neonc Technologies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05023018)) |
| December 2026 | [Qrx003, 4% lotion primary completion](https://sec-api.dev/pdufa/qrx003-4-lotion) | QNRX | Netherton Syndrome | scheduled | "NCT05789056 (Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05789056)) |
| December 2026 | [IBRANCE® (palbociclib) primary completion](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer | scheduled | "NCT05909397 (Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05909397)) |
| December 2026 | [FABHALTA® (iptacopan) primary completion](https://sec-api.dev/pdufa/iptacopan) | NVS | Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | scheduled | "NCT06388941 (Iptacopan in Patients With ANCA Associated Vasculitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388941)) |
| December 2026 | [Seltorexant primary completion](https://sec-api.dev/pdufa/seltorexant) | JNJ | Depressive Disorder, Major | scheduled | "NCT06559306 (Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06559306)) |
| December 2026 | [Decartes-08 primary completion](https://sec-api.dev/pdufa/decartes-08) | RNAC | Myasthaenia Gravis | scheduled | "NCT06799247 (Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Cartesian Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06799247)) |
| December 2026 | [Qrx003, 4% lotion primary completion](https://sec-api.dev/pdufa/qrx003-4-lotion) | QNRX | Netherton Syndrome | scheduled | "NCT06953466 (Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06953466)) |
| December 2026 | [Rabies vaccine (serum-free vero cell), freeze-dried primary completion](https://sec-api.dev/pdufa/rabies-vaccine-serum-free-vero-cell-freeze-dried) | SVA | Rabies | scheduled | "NCT07055295 (Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Sinovac Biotech Co., Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07055295)) |
| December 31, 2026 | [Autolus Therapeutics plc interim data readout](https://sec-api.dev/companies/autl/catalysts) | AUTL | refractory progressive forms of MS | scheduled | "The interim results and cash flows are not necessarily indicative of results and cash flows that may be expected for the year ending December 31, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000148/autl-20260930.htm)) |
| December 31, 2026 | [CalciMedica, Inc. topline data readout](https://sec-api.dev/companies/calc/catalysts) | CALC | acute kidney injury | scheduled | "Warrants were exercisable immediately upon issuance and will expire upon the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) 30 days following the Company's public disclosure of topline results from a Phase 2 clinical trial in patients with acute kidney injury." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1534133/000119312526455490/ck0001534133-20260930.htm)) |
| December 31, 2026 | [Ebribafusp trial start](https://sec-api.dev/pdufa/ebribafusp) | AKBA | three rare glomerular kidney diseases, with initial data | scheduled | "NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS payment upon the earlier of initiation of a Phase 2 clinical trial and December 31, 2026, (iv) will make certain milestone payments upon the achievement of specified commercial milestone events with respect to the net sales of ebribafusp up to an aggregate amount equal to $487.5 million, and (v) will make certain royalty payments based on the net sales of ebribafusp with royalty percentage tiers ranging from the low single digits to mid-teen percentages." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1517022/000151702226000051/akba-20260630.htm)) |
| December 2026 | [Imbruvica (ibrutinib) primary completion](https://sec-api.dev/pdufa/ibrutinib) | JNJ | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma | scheduled | "NCT01804686 (A Long-term Extension Study of PCI-32765 (Ibrutinib)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT01804686)) |
| December 2026 | [BRUKINSA® (zanubrutinib) primary completion](https://sec-api.dev/pdufa/zanubrutinib) | ONC | B-cell Malignancies | scheduled | "NCT04170283 (A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04170283)) |
| December 2026 | [Pf-07104091 monotherapy dose escalation primary completion](https://sec-api.dev/pdufa/pf-07104091-monotherapy) | PFE | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | scheduled | "NCT04553133 (PF-07104091 as a Single Agent and in Combination Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04553133)) |
| December 2026 | [Covid-19 vaccine primary completion](https://sec-api.dev/pdufa/covid-19-vaccine) | GOVX | COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia | scheduled | "NCT04977024 (SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor GeoVax, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04977024)) |
| December 2026 | [Talzenna (talazoparib tosylate) primary completion](https://sec-api.dev/pdufa/talazoparib) | PFE | Advanced Malignancies; NSCLC; Ovarian Cancer | scheduled | "NCT05059522 (Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05059522)) |
| December 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Cancer | scheduled | "NCT05303532 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05303532)) |
| December 2026 | [MN-001 primary completion](https://sec-api.dev/pdufa/mn-001) | MNOV | Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease | scheduled | "NCT05464784 (MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor MediciNova." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05464784)) |
| December 2026 | [Treprostinil palmitil primary completion](https://sec-api.dev/pdufa/treprostinil-palmitil) | INSM | Pulmonary Arterial Hypertension | scheduled | "NCT05649748 (An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05649748)) |
| December 2026 | [Cenerimod 4 mg primary completion](https://sec-api.dev/pdufa/cenerimod) | VTRS | Lupus Erythematosus, Systemic | scheduled | "NCT05672576 (A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05672576)) |
| December 2026 | [TEV-56248 primary completion](https://sec-api.dev/pdufa/tev-56248) | TEVA | Asthma | scheduled | "NCT06052267 (A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06052267)) |
| December 2026 | [Lisaftoclax +btk inhibitor primary completion](https://sec-api.dev/pdufa/lisaftoclax-btk-inhibitor) | AAPG | CLL/SLL | scheduled | "NCT06104566 (Global Trial in APG2575 for Patients With CLL/SLL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104566)) |
| December 2026 | [Ziihera® (zanidatamab) primary completion](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Breast Cancer; Gastric Cancer; Esophageal Cancer | scheduled | "NCT06695845 (A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06695845)) |
| December 2026 | [Spn-821 2400 mg primary completion](https://sec-api.dev/pdufa/spn-821) | SUPN | Major Depressive Disorder (MDD) | scheduled | "NCT07226661 (Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226661)) |
| December 2026 | [Xdemvy (lotilaner) primary completion](https://sec-api.dev/pdufa/lotilaner) | TARS | Ocular Rosacea | scheduled | "NCT07443202 (Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07443202)) |

Other months: https://sec-api.dev/fda-calendar/2026-11 , https://sec-api.dev/fda-calendar/2027-01. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates December 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-12

```bibtex
@misc{secapidev_fda_calendar_2026_12_20261116,
  title        = {PDUFA dates December 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-12}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_12_20261116","title":"PDUFA dates December 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-12","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
